Our study demonstrates that butyric acid has good therapeutic efficacy against C. jejuni infection in mice, and some studies have also shown that butyric acid promotes the antibacterial activity of intestinal macrophages in vivo, limits cell translocation in vivo (55) and protects mice from C. difficile-induced colitis through a HIF-1-dependent mechanism (56) and that the HIF-1 signaling pathway is regulated by the PI3K-Akt signaling pathway (57). Here, AKT1 is linked to colitis.